UA114289C2 - Неводні концентровані суспензійні композиції зі зниженою в'язкістю на основі антитіл - Google Patents
Неводні концентровані суспензійні композиції зі зниженою в'язкістю на основі антитілInfo
- Publication number
- UA114289C2 UA114289C2 UAA201311856A UAA201311856A UA114289C2 UA 114289 C2 UA114289 C2 UA 114289C2 UA A201311856 A UAA201311856 A UA A201311856A UA A201311856 A UAA201311856 A UA A201311856A UA 114289 C2 UA114289 C2 UA 114289C2
- Authority
- UA
- Ukraine
- Prior art keywords
- antibodies
- reduced viscosity
- concentrated suspension
- suspension compositions
- aqueous concentrated
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
Abstract
Даний винахід стосується неводної суспензійної композиції високої концентрації, що складається з: a) несучого середовища, що містить кунжутну олію як гідрофобний засіб і етилолеат як засіб, який знижує в'язкість; і b) антитіла в суміші з ексципієнтом, де антитілом є антитіло проти ФНО-α, яке містить варіабельну ділянку легкого ланцюга (VL) з SEQ ID NO: 7 (VH) і варіабельну ділянку важкого ланцюга з SEQ ID NO: 4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/043,925 US20110223208A1 (en) | 2010-03-09 | 2011-03-09 | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
PCT/US2011/054257 WO2012121754A1 (en) | 2011-03-09 | 2011-09-30 | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
UA114289C2 true UA114289C2 (uk) | 2017-05-25 |
Family
ID=46798862
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201311856A UA114289C2 (uk) | 2011-03-09 | 2011-09-30 | Неводні концентровані суспензійні композиції зі зниженою в'язкістю на основі антитіл |
Country Status (16)
Country | Link |
---|---|
US (1) | US20110223208A1 (uk) |
EP (1) | EP2683403B1 (uk) |
JP (1) | JP5881748B2 (uk) |
KR (1) | KR101949707B1 (uk) |
CN (1) | CN103402540A (uk) |
AU (1) | AU2011361700B2 (uk) |
BR (1) | BR112013023006A8 (uk) |
CA (1) | CA2829367A1 (uk) |
EA (1) | EA201391298A1 (uk) |
ES (1) | ES2743687T3 (uk) |
IL (1) | IL228211B (uk) |
MX (1) | MX351659B (uk) |
SG (1) | SG193278A1 (uk) |
UA (1) | UA114289C2 (uk) |
WO (1) | WO2012121754A1 (uk) |
ZA (2) | ZA201307513B (uk) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2547323B1 (en) | 2010-03-17 | 2016-01-27 | Novaliq GmbH | Pharmaceutical composition for treatment of increased intraocular pressure |
EP2444063A1 (en) | 2010-10-20 | 2012-04-25 | Novaliq GmbH | Liquid pharmaceutical compositions for the delivery of active ingredients |
EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
US8697644B2 (en) | 2011-03-10 | 2014-04-15 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
KR20140018966A (ko) * | 2011-04-07 | 2014-02-13 | 글락소스미스클라인 엘엘씨 | 점도가 감소된 제제 |
US10130707B2 (en) | 2011-05-25 | 2018-11-20 | Novaliq Gmbh | Topical pharmaceutical composition based on semifluorinated alkanes |
PT2806886T (pt) | 2012-01-23 | 2017-03-24 | Novaliq Gmbh | Composições de proteínas estabilizadas baseadas em alcanos semifluorados |
BR112014028600B1 (pt) * | 2012-05-18 | 2022-11-22 | Genentech, Inc | Formulações de suspensão compreendendo anticorpo monoclonal de alta concentração, seu método de preparação, seu uso e dispositivo para sua administração subcutânea, e método para produção de um artigo de fabricação |
JP2015519382A (ja) * | 2012-06-12 | 2015-07-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 治療用抗体のための医薬処方物 |
US9125805B2 (en) | 2012-06-27 | 2015-09-08 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of small molecule drugs |
JP6189437B2 (ja) * | 2012-07-17 | 2017-08-30 | バイエル・ニュージーランド・リミテッド | 注射用抗生物質製剤およびその使用方法 |
CA2883002C (en) | 2012-09-12 | 2019-05-21 | Novaliq Gmbh | Compositions comprising mixtures of semifluorinated alkanes |
EP4342537A2 (en) | 2012-09-12 | 2024-03-27 | Novaliq GmbH | Semifluorinated alkane compositions |
CA2906101A1 (en) * | 2013-03-15 | 2014-09-18 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
ES2687094T3 (es) | 2013-07-23 | 2018-10-23 | Novaliq Gmbh | Composiciones estabilizadas de anticuerpos |
EP3791862A1 (en) * | 2013-09-11 | 2021-03-17 | Eagle Biologics, Inc. | Liquid protein formulations containing viscosity-lowering agents |
EP2946767B1 (en) | 2014-05-23 | 2016-10-05 | Ares Trading S.A. | Liquid pharmaceutical composition |
ES2600488T3 (es) | 2014-05-23 | 2017-02-09 | Ares Trading S.A. | Composición farmacéutica líquida |
ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
AU2015280480A1 (en) * | 2014-06-26 | 2017-01-05 | Amgen Inc. | Protein formulations |
EP3871709A1 (en) | 2014-08-06 | 2021-09-01 | Xeris Pharmaceuticals, Inc. | Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes |
US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
US11590205B2 (en) | 2015-09-25 | 2023-02-28 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents |
JP6602964B2 (ja) | 2015-09-30 | 2019-11-06 | ノバリック ゲーエムベーハー | 半フッ素化化合物およびその組成物 |
EP4234523A1 (en) | 2015-09-30 | 2023-08-30 | Novaliq GmbH | Semifluorinated compounds for ophthalmic administration |
PL3442480T3 (pl) | 2016-06-23 | 2020-04-30 | Novaliq Gmbh | Sposób podawania miejscowego |
AU2017329772B2 (en) | 2016-09-22 | 2023-02-02 | Novaliq Gmbh | Pharmaceutical compositions for use in the therapy of blepharitis |
JP6869336B2 (ja) | 2016-09-23 | 2021-05-12 | ノバリック ゲーエムベーハー | シクロスポリンを含む眼科用組成物 |
JP7275027B2 (ja) * | 2016-10-06 | 2023-05-17 | アムジェン インコーポレイテッド | 粘度低下タンパク質医薬製剤 |
CN108686204A (zh) | 2017-04-07 | 2018-10-23 | 浙江海正药业股份有限公司 | 包含组氨酸缓冲体系的英夫利西单抗组合物 |
CN108686205B (zh) * | 2017-04-07 | 2021-12-10 | 海正生物制药有限公司 | 英夫利西单抗冻干制剂 |
AU2018253944B2 (en) | 2017-04-21 | 2022-09-15 | Dermaliq Therapeutics, Inc. | Iodine compositions |
EP3621601A1 (en) | 2017-05-12 | 2020-03-18 | Novaliq GmbH | Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions |
US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
CA3064840A1 (en) | 2017-06-02 | 2018-12-06 | Xeris Pharmaceuticals, Inc. | Precipitation resistant small molecule drug formulations |
CN107167613B (zh) * | 2017-06-22 | 2018-10-02 | 深圳清华大学研究院 | 用于等离子体金芯片的蛋白点样缓冲液 |
KR20200059272A (ko) | 2017-09-27 | 2020-05-28 | 노바리크 게엠베하 | 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물 |
WO2019068763A1 (en) | 2017-10-04 | 2019-04-11 | Novaliq Gmbh | OPHTHALMIC COMPOSITIONS COMPRISING F6H8 |
WO2019166631A1 (en) | 2018-03-02 | 2019-09-06 | Novaliq Gmbh | Pharmaceutical compositions comprising nebivolol |
EP3801469A4 (en) * | 2018-06-07 | 2022-03-09 | Merck Sharp & Dohme Corp. | KIT OF CRITICAL REAGENTS IN THE FORM OF LYOSPHERES |
US20200061015A1 (en) * | 2018-08-23 | 2020-02-27 | Janssen Biotech, Inc. | Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations |
AU2019358249B2 (en) | 2018-10-12 | 2024-02-22 | Novaliq Gmbh | Ophthalmic composition for treatment of dry eye disease |
KR20210093976A (ko) * | 2018-11-21 | 2021-07-28 | 리제너론 파아마슈티컬스, 인크. | 고농도 단백질 제형 |
AU2020219125A1 (en) | 2019-02-05 | 2021-08-12 | Lindy Biosciences, Inc. | Isolated cell culture components and methods for isolating the same from liquid cell culture medium |
MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
WO2021105392A1 (en) * | 2019-11-27 | 2021-06-03 | Novaliq Gmbh | Suspension comprising a protein particle suspended in a non-aqueous vehicle |
CN113698478A (zh) * | 2020-05-21 | 2021-11-26 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639587A (en) * | 1969-11-07 | 1972-02-01 | Eastman Kodak Co | Medicinal compositions for administration to animals and process for administering same |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DE19638045A1 (de) * | 1996-09-18 | 1998-03-19 | Bayer Ag | Injektionsformulierungen von Avermectinen und Milbemycinen |
IN184589B (uk) * | 1996-10-16 | 2000-09-09 | Alza Corp | |
US6169320B1 (en) | 1998-01-22 | 2001-01-02 | Raytheon Company | Spiral-shaped inductor structure for monolithic microwave integrated circuits having air gaps in underlying pedestal |
US7919109B2 (en) * | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
UA81743C2 (uk) * | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
AU1344102A (en) * | 2000-10-12 | 2002-04-22 | Genentech Inc | Reduced-viscosity concentrated protein formulations |
GB0113179D0 (en) * | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
EP1485066B1 (fr) * | 2002-03-12 | 2016-09-21 | Ethypharm | Composition a proprietes gelifiantes destinee a la delivrance prolongee de substances bio-actives |
RU2005133427A (ru) | 2003-03-31 | 2006-04-27 | Алза Корпорейшн (Us) | Безводные однофазные носители и препараты с использованием таких носителей |
DE10330235A1 (de) * | 2003-07-04 | 2005-01-20 | Bayer Healthcare Ag | Neues Eimeria Gen und Protein sowie deren Verwendung |
US8728525B2 (en) * | 2004-05-12 | 2014-05-20 | Baxter International Inc. | Protein microspheres retaining pharmacokinetic and pharmacodynamic properties |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
US20060142234A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
BRPI0717335A2 (pt) * | 2006-10-27 | 2013-12-10 | Abbott Biotech Ltd | Anticorpos anti-htnfalfa cristalinos |
US20090022727A1 (en) * | 2007-01-26 | 2009-01-22 | Alza Corp. | Injectable, nonaqueous suspension with high concentration of therapeutic agent |
US20090208492A1 (en) * | 2007-06-14 | 2009-08-20 | Elan Pharmaceuticals, Inc. | Lyophilized Immunoglobulin Formulations and Methods of Preparation |
US8563527B2 (en) * | 2007-08-20 | 2013-10-22 | Pharmain Corporation | Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same |
JP5711138B2 (ja) * | 2008-11-16 | 2015-04-30 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 高濃度の低粘度懸濁液 |
ES2659079T3 (es) | 2010-03-09 | 2018-03-13 | Janssen Biotech, Inc. | Formulaciones no acuosas en suspensión de viscosidad reducida a concentración elevada |
-
2011
- 2011-03-09 US US13/043,925 patent/US20110223208A1/en not_active Abandoned
- 2011-09-30 EP EP11860324.0A patent/EP2683403B1/en active Active
- 2011-09-30 AU AU2011361700A patent/AU2011361700B2/en not_active Ceased
- 2011-09-30 MX MX2013010335A patent/MX351659B/es active IP Right Grant
- 2011-09-30 JP JP2013557706A patent/JP5881748B2/ja active Active
- 2011-09-30 WO PCT/US2011/054257 patent/WO2012121754A1/en active Application Filing
- 2011-09-30 EA EA201391298A patent/EA201391298A1/ru unknown
- 2011-09-30 CN CN2011800691447A patent/CN103402540A/zh active Pending
- 2011-09-30 ES ES11860324T patent/ES2743687T3/es active Active
- 2011-09-30 KR KR1020137026423A patent/KR101949707B1/ko active IP Right Grant
- 2011-09-30 CA CA2829367A patent/CA2829367A1/en not_active Abandoned
- 2011-09-30 UA UAA201311856A patent/UA114289C2/uk unknown
- 2011-09-30 BR BR112013023006A patent/BR112013023006A8/pt not_active Application Discontinuation
- 2011-09-30 SG SG2013066204A patent/SG193278A1/en unknown
-
2013
- 2013-08-29 IL IL228211A patent/IL228211B/en active IP Right Grant
- 2013-10-08 ZA ZA2013/07513A patent/ZA201307513B/en unknown
-
2016
- 2016-02-05 ZA ZA2016/00811A patent/ZA201600811B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112013023006A2 (pt) | 2016-12-06 |
JP5881748B2 (ja) | 2016-03-09 |
AU2011361700A1 (en) | 2013-09-19 |
ZA201307513B (en) | 2018-12-19 |
KR20140145942A (ko) | 2014-12-24 |
MX2013010335A (es) | 2013-10-03 |
ES2743687T3 (es) | 2020-02-20 |
MX351659B (es) | 2017-10-23 |
CA2829367A1 (en) | 2012-09-13 |
CN103402540A (zh) | 2013-11-20 |
EA201391298A1 (ru) | 2014-02-28 |
EP2683403A4 (en) | 2014-10-08 |
EP2683403A1 (en) | 2014-01-15 |
KR101949707B1 (ko) | 2019-02-19 |
WO2012121754A1 (en) | 2012-09-13 |
US20110223208A1 (en) | 2011-09-15 |
EP2683403B1 (en) | 2019-06-19 |
BR112013023006A8 (pt) | 2017-12-19 |
AU2011361700B2 (en) | 2017-06-22 |
IL228211B (en) | 2018-04-30 |
ZA201600811B (en) | 2016-11-30 |
SG193278A1 (en) | 2013-10-30 |
JP2014510077A (ja) | 2014-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA114289C2 (uk) | Неводні концентровані суспензійні композиції зі зниженою в'язкістю на основі антитіл | |
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
CY1123958T1 (el) | Μεθοδος παρασκευης παραγωγων και ενδιαμεσων καρβαμοϋλπυριδονης | |
EA201890942A1 (ru) | Мультивалентные вакцины с синтетическими наноносителями | |
EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
EA201590993A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
EA201390145A1 (ru) | Конъюгаты, частицы, композиции и связанные с ними способы | |
EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
EA201892509A1 (ru) | Антитела к гемагглютинину и способы применения | |
EA201592213A1 (ru) | Антитела антирецептор трансферрина и способы их использования | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
EA201391175A1 (ru) | Гетеродимерные иммуноглобулины | |
EA201590887A1 (ru) | Композиция | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
EA201391489A1 (ru) | Композиции со сниженной вязкостью | |
EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
EA201390660A1 (ru) | Модифицированные никотиновые соединения и связанные способы | |
EA201490024A1 (ru) | Наполненные силиконовые композиции, их получение и применение | |
TR201903279T4 (tr) | Disülfür stabilize edilmiş DVD-IG molekülleri. | |
EA201391488A1 (ru) | Композиции со сниженной вязкостью | |
EA201490037A1 (ru) | Антагонисты trpv4 | |
EA201390467A1 (ru) | Композиции антител и способы применения | |
EA201491063A1 (ru) | Применение белков р3 бактериофага в качестве агентов, связывающих амилоид | |
EP2544721A4 (en) | NON-AQUEOUS AND HIGH-CONCENTRATED SUSPENSION FORMULATIONS OF REDUCED VISCOSITY |